David Baker’s lab shows generative AI can design antibodies. But are they good enough to become drugs?

Ryan Cross

Senior Science Correspondent

The promise of using artificial intelligence to design biologic drugs from scratch is starting to look a lot less abstract.
This week, scientists led by …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

David Baker’s lab shows generative AI can design antibodies. But are they good enough to become drugs?

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Exclusive: Florida cancer biotech raises $100M Series A

David Bak­er’s lab shows gen­er­a­tive AI can de­sign an­ti­bod­ies. But are they good enough to be­come drugs?

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

David Baker’s lab shows generative AI can design antibodies. But are they good enough to become drugs?

CagriSema’s weight loss data disappointed. What does Novo do next?

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Exclusive: Florida cancer biotech raises $100M Series A